WO2009001089A1 - Dérivés de thiazole fusionné comme inhibiteurs de kinase - Google Patents

Dérivés de thiazole fusionné comme inhibiteurs de kinase Download PDF

Info

Publication number
WO2009001089A1
WO2009001089A1 PCT/GB2008/002194 GB2008002194W WO2009001089A1 WO 2009001089 A1 WO2009001089 A1 WO 2009001089A1 GB 2008002194 W GB2008002194 W GB 2008002194W WO 2009001089 A1 WO2009001089 A1 WO 2009001089A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
aminocarbonyl
alkoxy
mmol
Prior art date
Application number
PCT/GB2008/002194
Other languages
English (en)
Inventor
Rikki Peter Alexander
Pavandeep Singh Aujla
Karen Viviane Lucile CRÉPY
Anne Marie Foley
Richard Jeremy Franklin
Original Assignee
Ucb Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB2007/002390 external-priority patent/WO2008001076A1/fr
Priority to ES08775774T priority Critical patent/ES2416364T3/es
Priority to NZ581919A priority patent/NZ581919A/en
Priority to SI200830975T priority patent/SI2170906T1/sl
Priority to MEP-2013-70A priority patent/ME01592B/me
Priority to BRPI0813777A priority patent/BRPI0813777B8/pt
Priority to MX2009013740A priority patent/MX2009013740A/es
Priority to RSP20130257 priority patent/RS52824B/en
Priority to EP08775774A priority patent/EP2170906B1/fr
Priority to PL08775774T priority patent/PL2170906T3/pl
Priority to CA2692085A priority patent/CA2692085C/fr
Priority to JP2010514106A priority patent/JP5570981B2/ja
Priority to EA201000038A priority patent/EA017187B1/ru
Priority to US12/666,481 priority patent/US8338592B2/en
Priority to AU2008269577A priority patent/AU2008269577B2/en
Priority to DK08775774.6T priority patent/DK2170906T3/da
Priority to CN200880024430XA priority patent/CN101687885B/zh
Application filed by Ucb Pharma S.A. filed Critical Ucb Pharma S.A.
Publication of WO2009001089A1 publication Critical patent/WO2009001089A1/fr
Priority to IL202659A priority patent/IL202659A0/en
Priority to ZA2009/08997A priority patent/ZA200908997B/en
Priority to HK10107097.5A priority patent/HK1140756A1/xx
Priority to US13/681,840 priority patent/US8710054B2/en
Priority to HRP20130523AT priority patent/HRP20130523T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • the present invention relates to a class of fused thiazole derivatives, and to their use in therapy. More particularly, the invention provides a family of 6,7-dihydro- [l,3]thiazolo[5,4-c]pyridin-4(5H)-one derivatives, which are substituted in the 2-position by a substituted morpholin-4-yl moiety. These compounds are selective inhibitors of phosphoinositide 3-kinase (PI3K) enzymes, and are accordingly of benefit as pharmaceutical agents, especially in the treatment of adverse inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive and ophthalmic conditions.
  • PI3K phosphoinositide 3-kinase
  • PI3K pathway is implicated in a variety of physiological and pathological functions that are believed to be operative in a range of human diseases.
  • PI3Ks provide a critical signal for cell proliferation, cell survival, membrane trafficking, glucose transport, neurite outgrowth, membrane ruffling, superoxide production, actin reorganization and chemotaxis (cf. S. Ward et al., Chemistry & Biology, 2003, 10, 207- 213; and S.G. Ward & P. Finan, Current Opinion in Pharmacology, 2003, 3, 426-434); and are known to be involved in the pathology of cancer, and metabolic, inflammatory and cardiovascular diseases (cf. M.P. Wymann et al., Trends in Pharmacol. Sci., 2003, 24, 366-376).
  • Aberrant upregulation of the PI3K pathway is implicated in a wide variety of human cancers (cf. S. Brader & S. A. Eccles, Tumori, 2004, 90, 2-8).
  • the compounds in accordance with the present invention are therefore beneficial in the treatment and/or prevention of various human ailments.
  • autoimmune and inflammatory disorders such as rheumatoid arthritis, multiple sclerosis, asthma, inflammatory bowel disease, psoriasis and transplant rejection; cardiovascular disorders including thrombosis, cardiac hypertrophy, hypertension, and irregular contractility of the heart (e.g.
  • neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, ⁇ untington's disease, stroke, amyotrophic lateral sclerosis, spinal cord injury, head trauma and seizures; metabolic disorders such as obesity and type 2 diabetes; oncological conditions including leukaemia, glioblastoma, lymphoma, melanoma, and human cancers of the liver, bone, skin, brain, pancreas, lung, breast, stomach, colon, rectum, prostate, ovary and cervix; pain and nociceptive disorders; and ophthalmic disorders including age- related macular degeneration (ARMD).
  • age- related macular degeneration AMD
  • the compounds in accordance with the present invention may be beneficial as pharmacological standards for use in the development of new biological tests and in the search for new pharmacological agents.
  • the compounds of this invention may be useful as radioligands in assays for detecting compounds capable of binding to human PDK enzymes.
  • WO 2006/114606 describes fused bicyclic thiazole derivatives as selective inhibitors of PB kinase enzymes which are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive and ophthalmic conditions.
  • Various fused thiazole derivatives are disclosed in Liebigs Annalen der Chemie,
  • PDK inhibitors having a binding affinity (IC 5 o) for the human PDK ⁇ and/or PDK ⁇ and/or PDK ⁇ and/or PDK ⁇ isoform of 50 ⁇ M or less, generally of 20 ⁇ M or less, usually of 5 ⁇ M or less, typically of 1 ⁇ M or less, suitably of 500 nM or less, ideally of 100 nM or less, and preferably of 20 nM or less (the skilled person will appreciate that a lower IC 5O figure denotes a more active compound).
  • IC 5 o binding affinity for the human PDK ⁇ and/or PDK ⁇ and/or PDK ⁇ and/or PDK ⁇ isoform of 50 ⁇ M or less, generally of 20 ⁇ M or less, usually of 5 ⁇ M or less, typically of 1 ⁇ M or less, suitably of 500 nM or less, ideally of 100 nM or less, and preferably of 20 nM or less (the skilled person will appreciate that a lower IC 5
  • the compounds of the invention may possess at least a 10-fold selective affinity, typically at least a 20-fold selective affinity, suitably at least a 50-fold selective affinity, and ideally at least a 100-fold selective affinity, for the human PDK ⁇ and/or PDK ⁇ and/or PDK ⁇ and/or PDK ⁇ isoform relative to other human kinases.
  • the compounds of the invention possess notable advantages in terms of their high potency and selectivity, demonstrable efficacy, and valuable pharmacokinetic properties (including clearance and bioavailability).
  • the present invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof:
  • R 11 represents hydrogen or Ci -6 alkyl
  • R 12 represents hydrogen; or Ci -6 alkyl, Ci -6 alkoxy, C 3-7 cycloalkyl, C 3-7 cycloalkyl(Ci -6 )alkyl, aryl, aryl(Ci -6 )alkyl, C 3-7 heterocycloalkyl, C 3-7 heterocycloalkyl- (Ci -6 )alkyl, heteroaryl or heteroaryl(Ci. 6 )alkyl, any of which groups may be optionally substituted by one or more substituents; or
  • R 11 and R 12 when taken together with the carbon atom to which they are both attached, represent C 3-7 cycloalkyl or C 3-7 heterocycloalkyl, either of which groups may be optionally substituted by one or more substituents;
  • T represents oxygen or N-R 25 ;
  • V represents carbon or nitrogen;
  • W represents carbon or nitrogen;
  • R 23 represents hydrogen, halogen, cyano, nitro, Ci -6 alkyl, hydroxy(Ci -6 )alkyl, trifluoromethyl, aryl(Ci -6 )alkyl, oxazolinyl, triazolyl, hydroxy, Ci -6 alkoxy, difluoromethoxy, trifluoromethoxy, C 3-7 cycloalkoxy, C 3-7 cycloalkyl(Ci -6 )alkoxy, morpholinyl(Ci -6 )alkoxy, aryloxy, aryl(Ci -6 )alkoxy, Ci -6 alkyl
  • R 24 represents hydrogen, halogen, Ci -6 alkoxy or di(Ci -6 )alkylaminocarbonyl; or R 23 and R 24 , when situated on adjacent carbon atoms, together represent methylenedioxy or difluoromethylenedioxy; and R 25 represents Ci -6 alkyl.
  • any of the groups in the compounds of formula (I) above is stated to be optionally substituted, this group may be unsubstituted, or substituted by one or more substituents. Typically, such groups will be unsubstituted, or substituted by one or two substitutents. Suitably, such groups will be unsubstituted or monosubstituted.
  • the salts of the compounds of formula (I) will be pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds of the invention or of their pharmaceutically acceptable salts.
  • Suitable pharmaceutically acceptable salts of the compounds of this invention include acid addition salts which may, for example, be formed by mixing a solution of the compound of the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, citric acid, tartaric acid or phosphoric acid.
  • a pharmaceutically acceptable salts thereof may include alkali metal salts, e.g. sodium or potassium salts; alkaline earth metal salts, e.g. calcium or magnesium salts; and salts formed with suitable organic ligands, e.g. quaternary ammonium salts.
  • solvates of the compounds of formula (I) above include within its scope solvates of the compounds of formula (I) above.
  • Such solvates may be formed with common organic solvents, e.g. hydrocarbon solvents such as benzene or toluene; chlorinated solvents such as chloroform or dichloromethane; alcoholic solvents such as methanol, ethanol or isopropanol; ethereal solvents such as diethyl ether or tetrahydrofuran; or ester solvents such as ethyl acetate.
  • the solvates of the compounds of formula (I) may be formed with water, in which case they will be hydrates.
  • Suitable alkyl groups which may be present on the compounds of the invention include straight-chained and branched Ci -6 alkyl groups, for example Ci -4 alkyl groups. Typical examples include methyl and ethyl groups, and straight-chained or branched propyl, butyl and pentyl groups. Particular alkyl groups include methyl, ethyl, n-propyl, isopropyl, «-butyl, sec-butyl, isobutyl, tert-buty ⁇ , 2,2-dimethylpropyl and 3-methylbutyl.
  • Ci -6 alkoxy such as "Ci -6 alkoxy”, “Ci -6 alkylthio”, “Ci -6 alkylsulphonyl” and “Ci -6 alkylamino” are to be construed accordingly.
  • Specific C 3-7 cycloalkyl groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • Suitable aryl groups include phenyl and naphthyl, preferably phenyl.
  • Suitable aryl(Ci -6 )alkyl groups include benzyl, phenyl ethyl, phenylpropyl and naphthylmethyl .
  • Suitable heterocycloalkyl groups which may comprise benzo-fused analogues thereof, include azetidinyl, tetrahydrofuranyl, dihydrobenzofuranyl, pyrrolidinyl, indolinyl, thiazolidinyl, imidazolidinyl, tetrahydropyranyl, chromanyl, piperidinyl, 1,2,3,4- tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, piperazinyl, 1,2,3,4-tetrahydro- quinoxalinyl, homopiperazinyl, mo ⁇ holinyl, benzoxazinyl and thiomorpholinyl.
  • Suitable heteroaryl groups include furyl, benzofuryl, dibenzofuryl, thienyl, benzothienyl, pyrrolyl, indolyl, pyrrolo[2,3-6]pyridinyl, pyrrolo[3,2-c]pyridinyl, pyrazolyl, pyrazolo[l,5- ⁇ ]pyridinyl, indazolyl, oxazolyl, benzoxazolyl, isoxazolyl, thiazolyl, benzothiazolyl, isothiazolyl, imidazolyl, benzimidazolyl, imidazo[l,2- ⁇ ]pyridinyl, imidazo[4,5-£]pyridinyl, imidazo[ 1 ,2- ⁇ ]pyrimidinyl, imidazo[ 1 ,2- ⁇ ]pyrazinyl, oxadiazolyl, thiadiazolyl, triazolyl, benzotriazolyl, tetrazol
  • halogen as used herein is intended to include fluorine, chlorine, bromine and iodine atoms, especially fluoro or chloro.
  • compounds of formula (I) may accordingly exist as enantiomers.
  • compounds of the invention possess two or more asymmetric centres, they may additionally exist as diastereomers.
  • the invention is to be understood to extend to all such enantiomers and diastereomers, and to mixtures thereof in any proportion, including racemates.
  • Formula (I) and the formulae depicted hereinafter are intended to represent all individual stereoisomers and all possible mixtures thereof, unless stated or shown otherwise.
  • Formula (I) and the formulae depicted hereinafter are intended to represent all individual tautomers and all possible mixtures thereof, unless stated or shown otherwise.
  • R 1 ' examples include hydrogen, methyl and ethyl. In one embodiment, R 1 ' is hydrogen. In another embodiment, R 11 is Ci -6 alkyl, especially methyl.
  • R 12 represents hydrogen; or Ci -6 alkyl, C 3-7 cycloalkyl or aryl, any of which groups may be optionally substituted by one or more substituents.
  • R 12 examples include halogen, cyano, nitro, Ci -6 alkyl, trifluoromethyl, hydroxy, Ci -6 alkoxy, difluoromethoxy, trifluoromethoxy, aryloxy, Ci -6 alkylthio, Ci -6 alkylsulphonyl, amino, Ci -6 alkylamino, di(Ci -6 )alkylamino, C 2-6 alkylcarbonylamino, C 2-6 alkoxycarbonylamino, Ci -6 alkylsulphonylamino, formyl, C 2-6 alkylcarbonyl, carboxy, C 2-6 alkoxycarbonyl, aminocarbonyl, Ci -6 alkylaminocarbonyl, di(Ci -6 )alkylaminocarbonyl, aminosulphonyl, Ci -6 alkylaminosulphonyl and di(Ci -6 )alkylaminosulphonyl; especially halogen, Ci -6 alkyl, triflu
  • R 12 examples include fluoro, chloro, bromo, cyano, nitro, methyl, trifluoromethyl, hydroxy, methoxy, difluoromethoxy, trifluoromethoxy, phenoxy, methylthio, methylsulphonyl, amino, methylamino, dimethylamino, acetylamino, methoxycarbonylamino, methylsulphonylamino, formyl, acetyl, carboxy, methoxycarbonyl, aminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, aminosulphonyl, methylaminosulphonyl and dimethylaminosulphonyl; especially chloro, methoxy or methylthio.
  • R 19 Typical values of R include hydrogen, methyl, w-propyl, isopropyl, isobutyl, cyclohexyl and phenyl.
  • a particular value of R 1 is methyl.
  • R 1 ' and R 1 may together form an optionally substituted spiro linkage.
  • R 1 ' and R 12 when taken together with the carbon atom to which they are both attached, may represent C 3-7 cycloalkyl or C 3-7 heterocycloalkyl, either of which groups may be unsubstituted, or substituted by one or more, typically by one or two, substituents.
  • R 1 ' and R 12 when taken together with the carbon atom to which they are both attached, may suitably represent an optionally substituted cyclopentyl, cyclohexyl, pyrrolidine or piperidine ring.
  • T is N-R 25 .
  • T is oxygen.
  • V is carbon. In another embodiment, V is nitrogen. In a preferred embodiment, W is carbon. In another embodiment, W is nitrogen.
  • R represents hydrogen, halogen, cyano, nitro, Ci -6 alkyl, hydroxy(Ci -6 )alkyl, trifiuoromethyl, aryl(Ci -6 )alkyl, hydroxy, Ci -6 alkoxy, difluoromethoxy, trifluoromethoxy, aryloxy, aryl(Ci.
  • Ci -6 alkylthio Ci -6 alkylsulphinyl, arylsulphinyl, arylsulphonyl, Ci -6 alkylsulphonyloxy, amino, C 2-6 alkylcarbonylamino, Ci -6 alkylsulphonylamino, C 2-6 alkylcarbonyl, carboxy, C 2-6 alkoxycarbonyl, aminocarbonyl, Ci -6 alkylaminocarbonyl, [hydroxy(Ci -6 )alkyl]amino- carbonyl, di(C i -6 )alkylaminocarbonyl, [(C i -6 )alkyl] [hydroxy(C i -6 )alkyl] aminocarbonyl, aryl(C i ⁇ alkylaminocarbonyl, azetidinylcarbonyl, pyrrolidinylcarbonyl, piperidinylcarbonyl, (Ci -6 )
  • the present invention further provides a compound of formula (I) as depicted above, or a pharmaceutically acceptable salt or solvate thereof, wherein R 23 represents hydrogen, halogen, cyano, Ci -6 alkyl, hydroxy(Ci -6 )alkyl, trifiuoromethyl, aryl(Ci -6 )alkyl, hydroxy, Ci -6 alkoxy, trifluoromethoxy, aryloxy, aryl(Ci -6 )alkoxy, Ci -6 alkylthio, Ci -6 alkylsulphinyl, arylsulphinyl, arylsulphonyl, Ci -6 alkylsulphonyloxy, amino, C 2-6 alkylcarbonylamino, Ci -6 alkylsulphonylamino, C 2-6 alkylcarbonyl or aminocarbonyl.
  • R 23 represents hydrogen, halogen, cyano, Ci -6 alkyl, hydroxy(Ci -6 )alkyl
  • R 23 Particular values of R 23 include hydrogen, halogen, cyano, nitro, oxazolinyl, triazolyl, Ci -6 alkoxy, difluoromethoxy, trifluoromethoxy, C 3-7 cycloalkoxy, C 3-7 cycloalkyl(Ci -6 )alkoxy, morpholinyl(Ci -6 )alkoxy, azetidinyl, morpholinyl, C 2-6 alkylcarbonylamino, C 2-6 alkylcarbonylaminomethyl, C 2-6 alkoxycarbonylamino, [(C 2-6 )alkoxycarbonyl][(Ci -6 )alkyl]amino, Ci -6 alkylsulphonylamino, C 2-6 alkylcarbonyl, C 2-6 alkylcarbonyl oxime, C 2-6 alkylcarbonyl O-(methyl)oxime, trifluoromethylcarbonyl, carboxy, C 2-6 al
  • Typical values of R include hydrogen, halogen, nitro, difluoromethoxy, trifluoromethoxy, carboxy, C 2-6 alkoxycarbonyl, Ci -6 alkylaminocarbonyl, [hydroxy- (C i -6 )alkyl]aminocarbonyl, di(C i -6 )alkylaminocarbonyl, [(C 1 .
  • R include hydrogen, Ci -6 alkyl, hydroxy, aryl(Ci. 6 )alkoxy and
  • Illustrative values of R 23 include hydrogen, fluoro, chloro, bromo, cyano, nitro, methyl, hydroxymethyl, trifluoromethyl, benzyl, hydroxy, methoxy, ethoxy, difluoromethoxy, trifluoromethoxy, phenoxy, benzyloxy, methylthio, methylsulphinyl, phenylsulphinyl, phenylsulphonyl, methylsulphonyloxy, amino, acetylamino, methylsulphonylamino, acetyl, carboxy, methoxycarbonyl, aminocarbonyl, methylaminocarbonyl, (hydroxyethyl)aminocarbonyl, dimethylaminocarbonyl, N- (hydroxyethyl)-N-methylaminocarbonyl, benzylaminocarbonyl, azetidinylcarbonyl, pyrrolidinylcarbonyl, piperidin
  • R examples include hydrogen, fluoro, chloro, bromo, cyano, methyl, hydroxymethyl, trifluoromethyl, benzyl, hydroxy, methoxy, ethoxy, trifluoromethoxy, phenoxy, benzyloxy, methylthio, methylsulphinyl, phenylsulphinyl, phenylsulphonyl, methylsulphonyloxy, amino, acetylamino, methylsulphonylamino, acetyl and aminocarbonyl; especially hydrogen, methyl, hydroxy, benzyloxy or methylsulphonyloxy.
  • R 23 Definitive values of R 23 include hydrogen, fluoro, chloro, cyano, nitro, oxazolinyl, triazolyl, methoxy, difluoromethoxy, trifluoromethoxy, cyclobutyloxy, cyclopropyl- methoxy, morpholinylethoxy, azetidinyl, morpholinyl, acetylamino, acetylaminomethyl, methoxycarbonylamino, N-methoxycarbonyl-N-methylamino, methylsulphonylamino, acetyl, acetyl oxime, acetyl 0-(methyl)oxime, trifluoromethylcarbonyl, carboxy, methoxycarbonyl, aminocarbonyl, methylaminocarbonyl, (hydroxyethyl)aminocarbonyl, (dimethylaminoethyl)aminocarbonyl, (1 -hydroxyprop-2-y
  • Selected values of R 23 include hydrogen, fluoro, nitro, difluoromethoxy, trifluoromethoxy, carboxy, methoxycarbonyl, methylaminocarbonyl, (hydroxyethyl)- aminocarbonyl, dimethylaminocarbonyl, N-(hydroxyethyl)-N-methylaminocarbonyl, benzylaminocarbonyl, azetidinylcarbonyl, piperidinylcarbonyl, methylpiperazinylcarbonyl and morpholinylcarbonyl .
  • R 23 may represent hydrogen, cyano, carboxy, C 2-6 alkoxycarbonyl, di(C )-6 )alkylaminocarbonyl, [(C i -6 )alkyl][cyano(Ci -6 )alkyl] aminocarbonyl, [(Ci -6 )alkoxy- (C i- ⁇ alkyl] [(C i -6 )alkyl] aminocarbonyl or azetidinylcarbonyl.
  • R 23 may represent hydrogen, cyano, carboxy, methoxycarbonyl, dimethylaminocarbonyl, N-(cyanomethyl)-N-methylaminocarbonyl, 7V-(methoxyethyl)-7V- methylaminocarbonyl or azetidinylcarbonyl.
  • R 23 is hydrogen. Another value of R 23 is cyano. Another value of R 23 is carboxy. Another value of R 23 is C 2-6 alkoxycarbonyl, especially methoxycarbonyl. A further value of R 3 is di(Ci -6 )alkylaminocarbonyl, especially dimethylaminocarbonyl. A further value of R 23 is [(Ci -6 )alkyl][cyano(Ci -6 )alkyl]amino- carbonyl, especially N-(cyanomethyl)-7V-methylaminocarbonyl. A still further value of R 23 is [(C i.
  • R 23 is azetidinylcarbonyl.
  • R 24 Definitive values of R 24 include hydrogen, chloro, methoxy and dimethylamino- carbonyl. A particular value of R 24 is hydrogen.
  • R 25 is suitably methyl.
  • Specific novel compounds in accordance with the present invention include each of the compounds whose preparation is described in the accompanying Examples, and pharmaceutically acceptable salts and solvates thereof.
  • the present invention also provides a pharmaceutical composition which comprises a compound in accordance with the invention as described above, or a pharmaceutically acceptable salt or solvate thereof, in association with one or more pharmaceutically acceptable carriers.
  • compositions according to the invention may take a form suitable for oral, buccal, parenteral, nasal, topical, ophthalmic or rectal administration, or a form suitable for administration by inhalation or insufflation.
  • the pharmaceutical compositions may take the form of, for example, tablets, lozenges or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methyl cellulose); fillers (e.g. lactose, microcrystalline cellulose or calcium hydrogenphosphate); lubricants (e.g. magnesium stearate, talc or silica); disintegrants (e.g. potato starch or sodium glycollate); or wetting agents (e.g. sodium lauryl sulphate).
  • binding agents e.g. pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methyl cellulose
  • fillers e.g. lactose, microcrystalline cellulose or calcium hydrogenphosphate
  • lubricants e.g. magnesium stearate, talc or silica
  • disintegrants e.g. potato starch or sodium glycollate
  • Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents, emulsifying agents, non-aqueous vehicles or preservatives.
  • the preparations may also contain buffer salts, flavouring agents, colouring agents or sweetening agents, as appropriate.
  • Preparations for oral administration may be suitably formulated to give controlled release of the active compound.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds of formula (I) may be formulated for parenteral administration by injection, e.g. by bolus injection or infusion.
  • Formulations for injection may be presented in unit dosage form, e.g. in glass ampoules or multi-dose containers, e.g. glass vials.
  • the compositions for injection may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising, preserving and/or dispersing agents.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g. sterile pyrogen-free water, before use.
  • the compounds of formula (I) may also be formulated as a depot preparation. Such long-acting formulations may be administered by implantation or by intramuscular injection.
  • the compounds according to the present invention may be conveniently delivered in the form of an aerosol spray presentation for pressurised packs or a nebuliser, with the use of a suitable propellant, e.g. dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
  • a suitable propellant e.g. dichlorodifluoromethane, fluorotrichloromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas or mixture of gases.
  • compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient.
  • the pack or dispensing device may be accompanied by instructions for administration.
  • the compounds according to the present invention may be conveniently formulated in a suitable ointment containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Particular carriers include, for example, mineral oil, liquid petroleum, propylene glycol, polyoxyethylene, polyoxypropylene, emulsifying wax and water.
  • the compounds according to the present invention may be formulated in a suitable lotion containing the active component suspended or dissolved in one or more pharmaceutically acceptable carriers.
  • Particular carriers include, for example, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, benzyl alcohol, 2- octyldodecanol and water.
  • the compounds according to the present invention may be conveniently formulated as microionized suspensions in isotonic, pH-adjusted sterile saline, either with or without a preservative such as a bactericidal or fungicidal agent, for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate.
  • a bactericidal or fungicidal agent for example phenylmercuric nitrate, benzylalkonium chloride or chlorhexidine acetate.
  • compounds may be formulated in an ointment such as petrolatum.
  • the compounds according to the present invention may be conveniently formulated as suppositories. These can be prepared by mixing the active component with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and so will melt in the rectum to release the active component.
  • suitable non-irritating excipient include, for example, cocoa butter, beeswax and polyethylene glycols.
  • daily dosages may range from around 10 ng/kg to 1000 mg/kg, typically from 100 ng/kg to 100 mg/kg, e.g. around 0.01 mg/kg to 40 mg/kg body weight, for oral or buccal administration, from around 10 ng/kg to 50 mg/kg body weight for parenteral administration, and from around 0.05 mg to around 1000 mg, e.g. from around 0.5 mg to around 1000 mg, for nasal administration or administration by inhalation or insufflation.
  • the compounds of formula (I) above may be prepared by a process which comprises reacting a compound of formula (II) with a compound of formula (III):
  • R 11 , R 12 , T, V, W, R 23 and R 24 are as defined above, and L 1 represents a suitable leaving group.
  • the leaving group L 1 is typically a halogen atom, e.g. bromo.
  • the reaction is conveniently effected at an elevated temperature in a suitable solvent, e.g. a lower alkanol such as isopropanol or a cyclic ether such as tetrahydrofuran, typically under basic conditions, e.g. in the presence of an organic base such as N,N- diisopropylethylamine or 2,6-lutidine.
  • a suitable solvent e.g. a lower alkanol such as isopropanol or a cyclic ether such as tetrahydrofuran
  • reaction may be effected at an elevated temperature in a solvent such as 2-ethoxyethanol in the presence of a catalytic quantity of a mineral acid, e.g. concentrated hydrochloric acid.
  • a solvent such as 2-ethoxyethanol
  • a catalytic quantity of a mineral acid e.g. concentrated hydrochloric acid.
  • the reaction may be effected at an elevated temperature in a suitable solvent, e.g. a cyclic ether such as tetrahydrofuran, or an aromatic solvent such as toluene, typically under basic conditions, e.g. in the presence of an inorganic base such as sodium tert-butoxide, in the presence of a transition metal catalyst.
  • a suitable solvent e.g. a cyclic ether such as tetrahydrofuran, or an aromatic solvent such as toluene
  • an inorganic base such as sodium tert-butoxide
  • the transition metal catalyst is suitably palladium(II) acetate, in which case the reaction will ideally be performed in the presence of tert-butylphosphonium tetrafluoroborate or dicyclohexyl diphenylphosphine.
  • R 1 ' and R 12 are as defined above; by diazotization/bromination.
  • reaction is conveniently effected by stirring compound (IV) with tert-butyl nitrite and copper(II) bromide in a suitable solvent, e.g. acetonitrile.
  • a suitable solvent e.g. acetonitrile.
  • L 2 represents a suitable leaving group.
  • the leaving group L 2 is typically a halogen atom, e.g. bromo.
  • the reaction is conveniently effected at an elevated temperature in a suitable solvent, e.g. a cyclic ether such as tetrahydrofuran, typically under basic conditions, e.g. in the presence of an organic base such as N,N-diisopropylethylamine.
  • a suitable solvent e.g. a cyclic ether such as tetrahydrofuran
  • an organic base such as N,N-diisopropylethylamine.
  • the reaction may be accomplished by heating the reactants in a lower alkanol solvent, e.g. a Ci -6 alkyl alcohol such as ethanol.
  • the compounds of formula (I) may be prepared by a process which comprises reacting a compound of formula (V) as defined above with a compound of formula (VI):
  • T, V, W, R 23 and R 24 are as defined above; under conditions analogous to those described above for the reaction between thiourea and compound (V).
  • the compounds of formula (I) wherein T is oxygen may be prepared by a process which comprises reacting a compound of formula (VII) with a compound of formula (VIII):
  • transition metal catalyst of use in the reaction between compounds (VII) and (VIII) is suitably palladium(H) acetate, in which case the reaction may conveniently be effected at an elevated temperature in a suitable solvent, e.g. a dipolar aprotic solvent such as N,N-dimethylformamide, in the presence of lithium chloride and a base, typically an inorganic base, e.g. an alkaline earth metal carbonate such as sodium carbonate.
  • a suitable solvent e.g. a dipolar aprotic solvent such as N,N-dimethylformamide
  • Removal of the trimethylsilyl moiety from the resulting cycloaddition product may be effected by treatment with an acid, e.g. a mineral acid such as hydrochloric acid.
  • an acid e.g. a mineral acid such as hydrochloric acid.
  • the trimethylsilyl moiety may be removed by treatment with a base, typically an inorganic base, e.g. an alkali metal hydroxide such as lithium hydroxide.
  • a base typically an inorganic base, e.g. an alkali metal hydroxide such as lithium hydroxide.
  • the intermediates of formula (VII) above may be prepared by reacting a compound of formula (V) as defined above with the compound of formula (IX):
  • the starting materials of formula (III), (V), (VI), (VIII) and (IX) may be prepared by methods analogous to those described in the accompanying Examples, or by standard methods well known from the art. It will be understood that any compound of formula (I) initially obtained from any of the above processes may, where appropriate, subsequently be elaborated into a further compound of formula (I) by techniques known from the art.
  • a compound of formula (I) wherein R 23 represents C 2-6 alkoxycarbonyl, e.g. methoxy- carbonyl may be converted into the corresponding compound wherein R represents carboxy (-CO 2 H) under standard saponification conditions, e.g. by treatment with a base such as lithium hydroxide.
  • a compound of formula (I) wherein R 23 represents carboxy (-CO 2 H) may be converted into the corresponding compound wherein R 23 contains an amido group, e.g. methylaminocarbonyl, 2-hydroxyethylaminocarbonyl, dimethylaminocarbonyl, N-(cyanomethyl)-N-methylaminocarbonyl, N-(2-hydroxyethyl)- N-methylaminocarbonyl, N-(2-methoxyethyl)-N-methylaminocarbonyl, benzylamino- carbonyl, azetidin-1-ylcarbonyl, pyrrolidin-1-ylcarbonyl, piperidin-1-ylcarbonyl, 4- methylpiperazin-1-ylcarbonyl or morpholin-4-ylcarbonyl, by a two-stage procedure which comprises (i) treatment of the carboxy derivative with pentafluorophenol in the presence of a condensing agent such as l-(3-
  • methylamine 2-hydroxyethylamine, dimethylamine, iV-(cyanomethyl)-iV-methylamine, N- (2-hydroxyethyl)-7V-methylamine, N-(2-methoxyethyl)-N-methylamine, benzylamine, azetidine, pyrrolidine, piperidine, 1-methylpiperazine or morpholine.
  • the desired product can be separated therefrom at an appropriate stage by conventional methods such as preparative HPLC; or column chromatography utilising, for example, silica and/or alumina in conjunction with an appropriate solvent system.
  • the diastereomers may then be separated by any convenient means, for example by crystallisation, and the desired enantiomer recovered, e.g. by treatment with an acid in the instance where the diastereomer is a salt.
  • a racemate of formula (I) may be separated using chiral HPLC.
  • a particular enantiomer may be obtained by using an appropriate chiral intermediate in one of the processes described above.
  • a particular enantiomer may be obtained by performing an enantiomer-specific enzymatic biotransformation, e.g. an ester hydrolysis using an esterase, and then purifying only the enantiomerically pure hydrolysed acid from the unreacted ester antipode. Chromatography, recrystallisation and other conventional separation procedures may also be used with intermediates or final products where it is desired to obtain a particular geometric isomer of the invention.
  • the compounds in accordance with this invention potently inhibit the activity of human PI3K ⁇ and/or PI3K ⁇ and/or PI3K ⁇ and/or PI3K ⁇ .
  • SiO 2 silica br.: broad w or wt: weight M: mass
  • NBS ⁇ f-bromosuccinimide brine: saturated aqueous sodium chloride solution
  • DIPEA ⁇ /,N-diisopropylethylamine
  • DMPU 1 ,3-dimethyl-3,4,5,6-tetrahydro-2(lH)-pyrimidinone
  • Method 1 Luna C 18(2) 100 x 4.6 mm, 5 ⁇ m column.
  • Mobile phase A 99.92% water, 0.08% formic acid.
  • Mobile phase B 99.92% MeCN, 0.08% formic acid.
  • Gradient program (flow rate 3.0 mL/min, column temperature 35°C): Time A % B % 0.00 95.0 5.0
  • Method 2 Luna C 18(2) 100 x 4.6 mm, 5 ⁇ m column.
  • Mobile phase A 5mM NH 4 OAc, pH 5.8.
  • Mobile phase B 95:5 MeCN : 10OmM NH 4 OAc, pH 5.8.
  • Gradient program (flow rate 3.0 mL/min, column temperature 35°C): Time A % B % 0.00 95.0 5.0
  • Method 3 Gemini Cl 8 50 x 4.6 mm, 5 ⁇ m column.
  • Mobile phase A 99.9% 1OmM ammonium formate, 0.1% formic acid.
  • Mobile phase B 94.9% MeCN, 0.1% formic acid, 5% mobile phase A.
  • Method 5 Gemini Cl 8 50 x 4.6 mm, 5 ⁇ m column.
  • Mobile phase A 99.9% ammonium formate, 0.1% formic acid.
  • Mobile phase B 94.9% MeCN, 0.1% formic acid, 5% mobile phase A.
  • Method 7 Gemini Cl 8 30 x 3.0 mm, 3 ⁇ m column.
  • Mobile phase A 99.9% 1OmM ammonium formate, 0.1% ammonia solution.
  • Mobile phase B 94.9% MeCN, 0.1% ammonia solution, 5% mobile phase A.
  • Method 9 Gemini Cl 8 30 x 3.0 mm, 3 ⁇ m column.
  • Mobile phase A 99.9% 1OmM ammonium formate, 0.1% ammonia solution.
  • Mobile phase B 100% MeCN.
  • Method 10 Luna C 18(2) 250 x 21.2 mm, 5 ⁇ m column.
  • Mobile phase A 99.92% water, 0.08% formic acid.
  • Mobile phase B 99.92% MeCN, 0.08% formic acid.
  • Gradient program flow rate 25.0 mL/min
  • column temperature ambient, variable gradient.
  • Method 11 Luna C 18(2) 250 x 21.2 mm, 5 ⁇ m column.
  • Mobile phase A 1OmM NH 4 OAc, pH 5.8.
  • Mobile phase B 95% MeCN, 5% 20OmM NH 4 OAc, pH 5.8.
  • Gradient program (flow rate 25.0 mL/min), column temperature: ambient, variable gradient.
  • Method 12 Gemini Cl 8 150 x 21.2 mm, 10 ⁇ m column.
  • Mobile phase A 99.9% ammonium formate, 0.1% formic acid.
  • Mobile phase B 94.9% MeCN, 0.1% formic acid, 5% mobile phase A.
  • Method 13 Gemini Cl 8 150 x 21.2 mm, 10 ⁇ m column.
  • Mobile phase A 99.9% ammonium formate, 0.1% ammonia solution.
  • Mobile phase B 94.9% MeCN, 0.1% ammonia solution, 5% mobile phase A.
  • Gradient program flow rate 20.0 mL/min
  • column temperature ambient, variable gradient.
  • the reaction mixture was concentrated in vacuo and the resultant white solid was dissolved in EtOAc (120 mL) and washed with aqueous NaOH solution (20% v/v, 2 x 100 mL). The organic fraction was then extracted into aqueous 2M HCl (2 x 150 mL). The combined acidic aqueous fractions were then basified to pH 14 (addition of solid NaOH) and were re-extracted with EtOAc (2 x 150 mL). The combined organic fractions were washed with brine (150 mL), dried (MgSO 4 ), filtered and concentrated in vacuo to give the title compound (13.5 g, 87%) as a clear oil that required no further purification.
  • Example 2 To a stirred solution of Example 2 (1.O g, 2.20 mmol) in DMF (20 mL) was added pentafluorophenol (0.49 g, 2.64 mmol), DIPEA (0.77 mL, 4.41 mmol) and EDC (0.55 g, 2.86 mmol). The reaction mixture was stirred at r.t. for 16 h, then concentrated in vacuo. DCM (15 mL) and water (15 mL) were added. The organic fraction was separated, dried (Na 2 SO 4 ), filtered and concentrated in vacuo. Purification by column chromatography (SiO 2 , 0-4% MeOH/DCM) gave the title compound (1.04 g, 76%) as a yellow gum. LCMS (ES+) 621.3 (M+H) + , RT 3.52 minutes ⁇ Method 4).
  • reaction mixture was quenched by the addition of 2M aqueous HCl (80 mL) and MeOH (50 mL), then stirred at r.t. for 3 h.
  • the reaction mixture was concentrated in vacuo.
  • the residue was dissolved in THF (60 mL).
  • DIPEA 4.9 mL, 28.4 mmol
  • l,l '-thiocarbonyldiimidazole 5.3 g, 29.7 mmol
  • the reaction mixture was stirred at r.t. for 16 h, then partitioned between DCM (50 mL) and water (30 mL). The organic fraction was dried (Na 2 SO 4 ), filtered and concentrated in vacuo.
  • aqueous phase was acidified to pH 1 by the addition of aqueous HCl (10% v/v) and extracted with EtOAc (3 x 200 mL) and the combined organic fractions were concentrated in vacuo to give the title compound (2.37 g, quantitative) as a yellow solid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

L'invention porte sur une série de dérivés de 6,7-dihydro[1,3]thiazolo[5,4-c]pyridin-4(5H)-one, qui sont substitués en position 2 par une fraction morpholine-4-yle substituée, étant des inhibiteurs sélectifs d'enzymes PI3 kinases. En conséquence, ces dérivés sont utiles en médecine, par exemple, dans le traitement d'états inflammatoires, auto-immuns, cardiovasculaires, neurodégénératifs, métaboliques, oncologiques, nociceptifs ou ophtalmiques.
PCT/GB2008/002194 2006-06-26 2008-06-24 Dérivés de thiazole fusionné comme inhibiteurs de kinase WO2009001089A1 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
NZ581919A NZ581919A (en) 2007-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors
EA201000038A EA017187B1 (ru) 2006-06-26 2008-06-24 Конденсированные производные тиазола в качестве ингибиторов киназ
JP2010514106A JP5570981B2 (ja) 2007-06-26 2008-06-24 キナーゼ阻害剤としての縮合チアゾール誘導体
MEP-2013-70A ME01592B (me) 2006-06-26 2008-06-24 Fuzionisani derivati tiazola kao inhibitori kinaze
BRPI0813777A BRPI0813777B8 (pt) 2007-06-26 2008-06-24 composto, composição farmacêutica, e, uso de um composto
MX2009013740A MX2009013740A (es) 2006-06-26 2008-06-24 Derivados de tiazol fusionados como inhibidores de cinasa.
RSP20130257 RS52824B (fr) 2006-06-26 2008-06-24
EP08775774A EP2170906B1 (fr) 2006-06-26 2008-06-24 Dérivés de thiazole fusionné comme inhibiteurs de kinase
PL08775774T PL2170906T3 (pl) 2006-06-26 2008-06-24 Pochodne skondensowanych tiazoli jako inhibitory kinaz
US12/666,481 US8338592B2 (en) 2006-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors
SI200830975T SI2170906T1 (sl) 2007-06-26 2008-06-24 Zliti derivati tiazola, kot inhibitorji kinaze
ES08775774T ES2416364T3 (es) 2006-06-26 2008-06-24 Derivados de tiazol condensados como inhibidores de cinasas
CA2692085A CA2692085C (fr) 2006-06-26 2008-06-24 Derives de thiazole fusionne comme inhibiteurs de kinase
AU2008269577A AU2008269577B2 (en) 2006-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors
DK08775774.6T DK2170906T3 (da) 2006-06-26 2008-06-24 Fusionerede thiazolderivater som kinaseinhibitorer
CN200880024430XA CN101687885B (zh) 2006-06-26 2008-06-24 作为激酶抑制剂的稠合噻唑衍生物
IL202659A IL202659A0 (en) 2006-06-26 2009-12-10 Fused thiazole derivatives as kinase inhibitors
ZA2009/08997A ZA200908997B (en) 2007-06-26 2009-12-17 Fused thiazole derivatives as kinase inhibitors
HK10107097.5A HK1140756A1 (en) 2007-06-26 2010-07-23 Fused thiazole derivatives as kinase inhibitors
US13/681,840 US8710054B2 (en) 2006-06-26 2012-11-20 Fused thiazole derivatives as kinase inhibitors
HRP20130523AT HRP20130523T1 (en) 2006-06-26 2013-06-12 Fused thiazole derivatives as kinase inhibitors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBPCT/GB2007/002390 2007-06-26
PCT/GB2007/002390 WO2008001076A1 (fr) 2006-06-26 2007-06-26 Dérivés de thiazole à cycle fusionnés en tant qu'inhibiteurs de kinase

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/666,481 A-371-Of-International US8338592B2 (en) 2006-06-26 2008-06-24 Fused thiazole derivatives as kinase inhibitors
US13/681,840 Continuation US8710054B2 (en) 2006-06-26 2012-11-20 Fused thiazole derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
WO2009001089A1 true WO2009001089A1 (fr) 2008-12-31

Family

ID=39737000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2008/002194 WO2009001089A1 (fr) 2006-06-26 2008-06-24 Dérivés de thiazole fusionné comme inhibiteurs de kinase

Country Status (8)

Country Link
JP (1) JP5570981B2 (fr)
KR (1) KR101577314B1 (fr)
BR (1) BRPI0813777B8 (fr)
HK (1) HK1140756A1 (fr)
NZ (1) NZ581919A (fr)
SI (1) SI2170906T1 (fr)
UA (1) UA99469C2 (fr)
WO (1) WO2009001089A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012071511A1 (fr) * 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazépines en tant qu'inhibiteurs de mtor et procédés de leurs utilisation et fabrication
JP2012527471A (ja) * 2009-05-20 2012-11-08 グラクソスミスクライン エルエルシー Ｐｉ３キナーゼ阻害剤としてのチアゾロピリミジノン誘導体
WO2020056269A1 (fr) * 2018-09-13 2020-03-19 Stemline Therapeutics, Inc. Méthodes de traitement de la myopathie centronucléaire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114606A1 (fr) * 2005-04-26 2006-11-02 Ucb Pharma S.A. Derives de thiazole fusionne en tant qu'inhibiteurs de la kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006114606A1 (fr) * 2005-04-26 2006-11-02 Ucb Pharma S.A. Derives de thiazole fusionne en tant qu'inhibiteurs de la kinase

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012527471A (ja) * 2009-05-20 2012-11-08 グラクソスミスクライン エルエルシー Ｐｉ３キナーゼ阻害剤としてのチアゾロピリミジノン誘導体
WO2012071511A1 (fr) * 2010-11-24 2012-05-31 Exelixis, Inc. Benzoxazépines en tant qu'inhibiteurs de mtor et procédés de leurs utilisation et fabrication
WO2020056269A1 (fr) * 2018-09-13 2020-03-19 Stemline Therapeutics, Inc. Méthodes de traitement de la myopathie centronucléaire

Also Published As

Publication number Publication date
UA99469C2 (ru) 2012-08-27
BRPI0813777A2 (pt) 2014-12-30
SI2170906T1 (sl) 2013-07-31
JP5570981B2 (ja) 2014-08-13
BRPI0813777B1 (pt) 2020-12-08
HK1140756A1 (en) 2010-10-22
KR101577314B1 (ko) 2015-12-14
JP2011504164A (ja) 2011-02-03
KR20100040736A (ko) 2010-04-20
BRPI0813777B8 (pt) 2021-05-25
NZ581919A (en) 2011-08-26

Similar Documents

Publication Publication Date Title
US8710054B2 (en) Fused thiazole derivatives as kinase inhibitors
AU2006239018B2 (en) Fused thiazole derivatives as kinase inhibitors
EP2499144B1 (fr) Dérivés quinoline et quinoxaline en tant qu' inhibiteurs de kinase
US20120095005A1 (en) Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors
WO2009071888A1 (fr) Pyrrolothiazoles comme inhibiteurs de la pi3 kinase
WO2009071890A1 (fr) Inhibiteurs tricycliques de kinase
EP2315768A1 (fr) Dérivés de thiéno-pyridine utilisés comme inhibiteurs de mek
WO2011058109A1 (fr) Dérivés de pyrrole et d'imidazole bicycliques condensés en tant qu'inhibiteurs de kinase
IL192603A (en) Thiano-pyridine derivatives such as mek inhibitors and their uses in the preparation of drugs for the treatment and / or prevention of inflammatory diseases, autoimmune diseases, heart diseases, proliferative diseases, cancers and in the treatment of pain related to the peripheral nervous system
US8168634B2 (en) Thiazole derivatives as kinase inhibitors
WO2009093013A1 (fr) Dérivés de thiophène condensés servant d'inhibiteurs de mek
WO2009001089A1 (fr) Dérivés de thiazole fusionné comme inhibiteurs de kinase
WO2011058112A1 (fr) Dérivés de pyrazole bicycliques condensés en tant qu'inhibiteurs de kinase
WO2010146351A1 (fr) Derives d'indolylmethyl-morpholine en tant qu'inhibiteurs des kinases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880024430.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08775774

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 581919

Country of ref document: NZ

Ref document number: 12009502401

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/013740

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2692085

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 8429/DELNP/2009

Country of ref document: IN

Ref document number: 2008269577

Country of ref document: AU

Ref document number: 2009121875

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 2010514106

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 09149835

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 201000038

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2008775774

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107001844

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A201000774

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2008269577

Country of ref document: AU

Date of ref document: 20080624

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PI 20095404

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 12666481

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: P-2013/0257

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0813777

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091223